Research Article
There Is No Impact of Diabetes on the Endothelial Function of Chronic Kidney Disease Patients
Table 1
Clinic characteristics of the study population.
| | CKD group () | CKD-DM group () | |
| | Age, years | 65.9 ± 13.9 | 64.1 ± 9.9 | 0.54 | | Male, (%) | 21 (56.8%) | 22 (59.5%) | 0.814 | | Hypertension, (%) | 35 (97.2%) | 34 (94.4%) | 0.555 | | Chronic kidney disease etiology, (%) | | | <0.001 | | Diabetes | 0 (0%) | 33 (89.2%) | | | Undetermined | 19 (51.4%) | 1 (2.7%) | | | Hypertension | 7 (18.9%) | 0 | | | Glomerulopathy | 5 (13.5%) | 0 | | | Others | 6 (16.2%) | 3 (8.1%) | | | Cardiovascular disease, (%) | 12 (32.4%) | 19 (51.4%) | 0.099 | | Myocardial infarction | 1 (2.7%) | 7 (18.9%) | 0.025 | | Myocardial revascularization | 0 (0%) | 4 (10.8%) | 0.04 | | Cerebrovascular accident | 5 (13.5%) | 4 (10.8%) | 0.722 | | Peripheral artery disease | 7 (18.9%) | 14 (37.8%) | 0.071 | | Drugs, (%) | | | | | ACEI/ARB | 27 (75%) | 33 (91.7%) | 0.058 | | Calcium channel blockers | 27 (75%) | 17 (47.2%) | 0.016 | | Diuretics | 25 (69.4%) | 34 (94.4%) | 0.006 | | Vasodilator | 2 (5.6%) | 7 (19.4%) | 0.075 | | Lipid-lowering agents | 24 (68.6%) | 30 (85.7%) | 0.088 | | Acetylsalicylic acid | 14 (38.9%) | 27 (73%) | 0.003 | | Systolic blood pressure, mmHg | 130 (125–140) | 140 (123.5–158.5) | 0.214 | | Diastolic blood pressure, mmHg | 80 (70–90) | 77 (70–84) | 0.343 | | Body mass index, kg/m2 | 27.7 ± 4.7 | 31.4 ± 5.7 | 0.004 | | Waist-hip circumference ratio | 0.97 ± 0.07 | 1.00 ± 0.06 | 0.032 |
|
|
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker.
|
